TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/642,365
Filing Date	August 14, 2003
First Named Inventor	Michael S. H. Chu
Art Unit	3731
Examiner Name	Not Yet Assigned
Attorney Docket Number	MIY-P03-024

	EN	CLOSURES (Check all that app	oly)		
Fee Transn	nittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)		
Fee Attach	ed	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendmen	nt/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Petition to Convert to a Provisional Application	Proprietary Information		
Affidavits/d	eclaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter		
Extension of	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):		
	eandonment Request	Request for Refund	IDS Form SB/08 (7 pages) References A1-A188, B1-B28 and C1-C41		
X Information (3 pages)	Disclosure Statement	CD, Number of CD(s)	3. Copy of the International Search Report (11 page)		
Certified Co	opy of Priority s)		Return Receipt Postcard		
	to Missing Parts/ Application	Remarks			
Response to	o Missing Parts under 37 r 1.53				
	SIGNATI	JRE OF APPLICANT, ATTORNEY, OF	RAGENT		
Firm or Individual name	ROPES & GRAY LL Weishi Li - 53,217	P			
Signature	425				
Date	November 18, 2004				

an envelope addressed to: MS Amendm	is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in ent, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
shown below. Dated: //-/8 -04	Signature: Maura A. Billy Ac(Maura A. Gallagher)
Dated:	Signature: // Kull Kr. Kully (Maura A. Gallagher)

NOV 2 2 2004 J

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11-18-04 ·

Signature: //awa.w., Salla (Maura A., Gallagher) Docket No.: MIY-P03-024

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Chu et al.

Application No.: 10/642,365

Confirmation No.: 1647

Filed: August 14, 2003

Art Unit: 3731

For:

SYSTEMS, METHODS AND DEVICES

Examiner: Not Yet Assigned

RELATING TO DELIVERY OF MEDICAL IMPLANTS

INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of the non US references listed on the PTO/SB/08 is attached. A summary/abstract translation of the non-English language references is enclosed where applicable.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: 10/642,365 Docket No.: MIY-P03-024

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicants call the Examiner's attention to office actions which may have issued in the following co-pending, co-owned patent applications of which subject matters are related to that of the instant application:

U.S. Patent Application	Filing Date
Serial Number	
10/093,371	March 7, 2002
10/002 200	March 7, 2002
10/093,398	March 7, 2002
10/093,424	March 7, 2002
10/053,121	1,1011 /, 2002
10/093,450	March 7, 2002
10/093,498	March 7, 2002
10/094,354	March 7, 2002
10/642,395	August 14, 2003
10/042,393	August 14, 2003
10/642,397	August 14, 2003
,	
10/641,487	August 14, 2003

Applicants have become aware of the following documents: U.S. Patent No. 6,312,448; U.S. Patent No. 5,904,692; WO 00/74594; EP 1159920; and U.S. Patent No. 5,899,909, cited in

Application No.: 10/642,365 Docket No.: MIY-P03-024

an International Search Report issued <u>August 20, 2004</u>, during the prosecution of international application no. PCT/US03/25568, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the International Search Report and each document cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

The undersigned hereby certifies that each item contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. MIY-P03-024.

Dated: November 18, 2004

Respectfully submitted,

Weishi Li

Registration No.: 53,217 ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Substitute for form 1449A/B/PTO

RADEM!

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 7

Complete if Known					
Application Number 10/642,365					
Filing Date	August 14, 2003				
First Named Inventor	Michael S. H. Chu				
Art Unit	N/A				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	MIY-P03-024				

Examiner Initials*	olumns, Lines, Where Passages or Relevant igures Appear
No. Number-Kind Code ² (if known) MM-DD-YYYY Applicant of Cited Document Reservant	
A2 2,738,790 3/20/56 Todt Sr., et al. A3 2,751,903 6/26/56 Ivory et al. A4 2,917,878 12/22/59 Edwin et al. A5 3,472,232 10/14/69 Earl et al. A6 3,565,073 2/23/71 Giesy A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,63860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,367,816 1/11/82 Altshuler A17 4,367,816 1/11/88 Wikes A18 4,422,567 12/27/83 Haynes A20 4,535,768 8/20/85 Hourahane et al. A21	
A3 2,751,903 6/26/56 Ivory et al. A4 2,917,878 12/22/59 Edwin et al. A5 3,472,232 10/14/69 Earl et al. A6 3,565,073 2/23/71 Giesy A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22	
A4 2,917,878 12/22/59 Edwin et al. A5 3,472,232 10/14/69 Earl et al. A6 3,565,073 2/23/71 Giesy A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22	
A5 3,472,232 10/14/69 Earl et al. A6 3,565,073 2/23/71 Giesy A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A6 3,565,073 2/23/71 Giesy A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,137 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A7 3,699,969 10/24/72 Allen A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A8 3,704,712 11/28/72 Giesy et al. A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A9 3,710,795 1/16/73 Higuchi et al. A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,76,337 10/11/88 Palmaz A27 <	
A10 3,763,860 10/9/73 Clarke A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,138 11/15/88 Sinnett A29 4	
A11 3,875,937 4/8/75 Schmitt et al. A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,798,193 1/17/89 Giesy et al.	
A12 3,877,434 4/15/75 Ferguson et al. A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A13 3,937,223 2/10/76 Roth A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A14 3,995,619 12/7/76 Glatzer A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A15 4,172,458 10/30/79 Pereyra A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayners A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A16 4,363,319 12/14/82 Altshuler A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A17 4,367,816 1/11/83 Wilkes A18 4,422,567 12/27/83 Haynes A19 4,445,898 5/1/84 Jensen A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A18	
A20 4,535,768 8/20/85 Hourahane et al. A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A21 4,592,339 6/3/86 Kuzmak et al. A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A22 4,606,335 8/19/86 Wedeen A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A23 4,739,751 4/26/88 Sapega et al. A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A24 4,741,330 5/3/88 Hayhurst A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A25 4,744,353 5/17/88 McFarland A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A26 4,776,337 10/11/88 Palmaz A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A27 4,784,137 11/15/88 Kulik et al. A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
A28 4,784,138 11/15/88 Sinnett A29 4,798,193 1/17/89 Giesy et al.	
1.00 1.00 1.00	
A30 4,824,435 4/25/89 Giesy et al.	
A31 4,872,451 10/10/89 Moore et al.	
A32 4,873,977 10/17/89 Avant et al.	
A33 4,874,375 10/17/89 Ellison	
A34 4,896,668 1/30/90 Popoff et al.	
A35 4,920,958 5/1/90 Walt et al.	
A36 4,927,420 5/22/90 Newkirk et al.	
A37 4,938,760 7/3/90 Burton et al.	
A38 4,946,468 8/7/90 Li	
A39 4,983,168 1/8/91 Moorehead	
A40 4,988,339 1/29/91 Vadher	
A41 5,002,550 3/26/91 Li	
A42 5,013,292 5/7/91 Lemay	
A43 5,064,435 11/12/91 Porter	
A44 5,078,730 1/7/92 Li	
A45 5,084,058 1/28/92 Li	
A46 5,085,661 2/4/94 Moss	

Examiner	Date
Signature	Considered

Substitute for form 1449A/B/PTO				Complete if Known		
		. +		Application Number	10/642,365	
IN	IFORMATION	N DI	SCLOSURE	Filing Date	August 14, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Michael S. H. Chu	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	7	Attorney Docket Number	MIY-P03-024	

A47	5,087,263	2/11/92	Li	
A48	5,089,013	2/18/92	Bezwada et al.	
A49	5,112,344	5/12/92	Petros	
A50	5,133,723	7/28/92	Li et al.	
A51	5,149,329	9/22/92	Richardson	
A52	5,152,749	10/6/92	Giesy et al.	
A53	5,163,946	11/17/92	Li	
A54	5,167,634	12/1/92	Corrigan Jr. et al.	
A55	5,188,636	2/23/93	Fedotov	
A56	5,203,784	4/20/93	Ross et al.	
A57	5,207,679	5/4/93	Li	
A58	5,222,508	6/29/93	Contarini	
A59	5,234,457	8/10/93	Andersen	
A60	5,250,033	10/5/93	Evans	
A61	5,256,133	10/26/93	Spitz	
A62	5,279,311	1/18/94	Snyder	
A63	5,281,237	1/25/94	Gimpelson	
A64	5,282,812	2/1/94	Suarez Jr.	
A65	5,334,185	8/2/94	Giesy et al.	
A66	5,337,736	8/16/94	Reddy	
A67	5,354,292	10/11/94	Braeuer et al.	
A68	5,368,595	11/29/94	Lewis	
A69	5,409,469	4/25/95	Schaerf	
A70	5,417,226	5/23/95	Juma	
A71	5,431,173	7/11/95	Chin et al.	
A72	5,439,467	8/8/95	Benderev et al.	
A73	5,441,502	8/15/95	Bartlett	
A74	5,474,543	12/12/95	McKay	
A75	5,499,991	3/19/96	Garman et al.	
A76	5,505,735	4/9/96	Li	
A77	5,544,664	8/13/96	Benderev et al.	
A78	5,562,717	10/8/96	Tippey et al.	
A79	5,582,188	12/10/96	Benderev et al	
A80	5,591,163	1/7/97	Thompson	
A81	5,611,515	3/18/97	Benderev et al.	
A82	5,620,012	4/15/97	Benderev et al.	
A83	5,624,446	4/29/97	Harryman II	
A84	5,637,112	6/10/97	Moore et al.	
A85	5,643,288	7/1/97	Thompson	
A86	5,645,589	7/8/97	Li	
A87	5,647,857	7/25/97	Anderson et al.	
A88	5,683,418	11/4/97	Luscombe et al.	
A89	5,690,649	11/25/97	Thompson	
A90	5,697,931	12/16/97 12/23/97	Thompson II	
A91	5,700,266		Harryman II	
A92	5,700,286	12/23/97 11/30/97	Tartaglia et al.	-
A93 A94	5,702,215	4/28/98	Chen	
A94 A95	5,742,943 5,749,884	5/12/98	Benderev et al.	
A95 A96	5,766,221	6/16/98	Benderev et al.	
IV90	10,700,221	0/10/30	ponderev et al.	l

Examiner	Date	
Signature	 Considered	

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/642,365	
II.	NFORMATIO	N DIS	CLOSURE	Filing Date	August 14, 2003	
S	TATEMENT	BY AF	PPLICANT	First Named Inventor	Michael S. H. Chu	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	7	Attorney Docket Number	MIY-P03-024	

A9	7	5,776,184	7/7/98	Tuch	
A9		5,813,408	9/29/98	Benderev et al.	
A9		5,816,258	10/6/98	Jervis	
		5,824,049	10/20/98	Ragheb et al.	
	01	5,836,314	11/17/98	Benderev et al.	
	02	5,836,315	11/17/98	Benderev et al.	
	103	5,840,011	11/24/98	Landgrebe et al.	
		5,842,478	12/1/98	Benderev et al.	
		5,899,909	5/4/99	Ulmsten et al.	
	06	5,904,692	5/18/99	Jacob et al.	
	107	5,935,122	8/10/99	Fourkas et al.	
		5,954,057	9/21/99	Li	
A1		5,997,541	12/7/99	Schenk	
A1		6,001,104	12/14/99	Benderev et al.	
A1	111	6,039,686	3/21/00	Kovac	
A1	112	6,042,534	3/28/00	Gellman et al.	
		6,042,583	3/28/00	Thompson et al.	
A1	114	6,050,937	4/18/00	Benderev	
A1	115	6,056,688	5/2/00	Benderev et al.	
A1	116	6,059,801	5/9/00	Samimi	
A1	117	6,077,216	6/20/00	Benderev et al.	
A1	118	6,096,041	8/1/00	Gellman et al.	
A1	119	6,099,538	8/8/00	Moses et al.	
A1	120	6,099,547	8/8/00	Gellman et al.	
	121	6,117,067	9/12/99	Gil-Vernet	
		6,200,330	3/13/01	Benderev et al.	
		6,245,082	6/12/01	Gellman et al.	
A1		6,264,676	6/24/01	Gellman et al.	
A1	125	6,273,852	8/14/01	Lehe et al.	
	126	6,299,607	10/9/01	Osborn, III et al.	
	127	6,312,448 B1	11/6/01	Bonutti	
		6,322,492	11/27/01	Kovac	
		6,328,686	12/11/01	Kovac	
		6,382,214	5/7/02	Raz et al.	
		6,406,423	6/18/02	Scetbon	
		6,423,080	7/23/02	Gellman et al.	
		6,440,154	8/27/02	Gellman et al.	
		6,478,727	11/12/02	Scetbon	
		6,478,763	11/12/02	Simonsen et al.	
		6,491,703	12/10/02	Ulmsten	
		6,494,887	12/17/02	Kaladelfos	
	138	6,500,194	12/31/02	Benderev et al.	
		6,502,578	1/7/03	Raz et al.	
	140	6,530,943	3/11/03	Hoepffner et al.	
	141	6,605,097	8/12/03	Lehe et al.	
	142	6,612,977	9/2/03	Staskin et al.	
	143	6,638,209	10/28/03	Landgrebe	
	144	6,638,210	10/28/03	Berger	
	145	6,638,211	10/28/03	Suslian et al.	
<u> A1</u>	146	6,641,525	11/4/03	Rocheleau et al.	

Examiner	Date
Signature	Considered

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/642,365 **INFORMATION DISCLOSURE** August 14, 2003 Filing Date STATEMENT BY APPLICANT Michael S. H. Chu First Named Inventor N/A Art Unit (Use as many sheets as necessary) Not Yet Assigned Examiner Name 4 7 MIY-P03-024 Sheet of Attorney Docket Number

	6,648,921	11/18/03	Anderson et al.
	6,652,450	11/25/03	Neisz et al.
	6,685,629	2/3/04	Therin
	2001/0000533	4/26/01	Kovac
A151	2001/0018549	8/30/01	Scetbon
	2001/0023356	9/20/01	Raz et al.
	2001/0049467	12/6/01	Lehe et al.
A154	2002/0013590	1/31/02	Therin et al.
A155	2002/0022841	2/21/02	Kovac
A156	2002/0055748	5/9/02	Gellman et al.
A157	2002/0068948	6/6/02	Stormby et al.
A158	2002/0072694	6/13/02	Snitkin
A159	2002/0077526	6/20/02	Kammerer et al.
A160	2002/0082619	6/27/02	Cabak et al.
A161	2002/0091298	7/11/02	Landgrebe
A162	2002/0091373	7/11/02	Berger
A163	2002/0099258	7/25/02	Staskin et al.
A164	2002/0099259	7/25/02	Anderson et al.
A165	2002/0099260	7/25/02	Suslian et al.
A166	2002/0107430	8/8/02	Neisz et al.
A167	2002/0116025	8/22/02	Haab
A168	2002/0128670	9/12/02	Ulmsten et al.
A169	2002/0138025	9/26/02	Gellman et al.
A170	2002/0147382	10/10/02	Neisz et al.
A171	2002/0151762	10/17/02	Rocheleau et al.
A172	2002/0151910	10/17/02	Gellman et al.
A173	2002/0161382	10/31/02	Neisz et al.
A174	2002/0165566	11/7/02	Ulmsten
A175	2002/0188169	12/12/02	Kammerer et al.
A176	2003/0004395	1/2/03	Therin
A177	2003/0004580	1/2/03	Sump et al.
A178	2003/0010929	1/16/03	Priewe et al.
A179	2003/0023138	1/30/03	Luscombe
A180	2003/0036676	2/20/03	Scetbon
A181	2003/0045774	3/6/03	Staskin et al.
A182	2003/0045892	3/6/03	Kaladellos
A183	2003/0050530	3/13/03	Neisz et al.
A184	2003/0100954	5/29/03	Schuldt-Hempe et al.
A185	2003/0130670	7/10/03	Anderson et al.
A186	2003/0176762	9/18/03	Kammerere
A187	2003/0191480	10/9/03	Ulmsten
A188	2004/0015048	1/22/04	Neisz et al.

			FOREIG	ON PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication	Name of Patentee or	Pages, Columns, Lines,	
		Country Code ³ -Number ⁴ -Kind Co	ode ⁵ (if known)	Date MM-DD-YYYY	vynere releval	Where Relevant Passages or Relevant Figures Appear	
	B1	DE 2,305,815 A1	8/8/7	4			
	B2	DE 2,532,242 A1	2/10/	77			

Examiner	Date
Signature	Considered

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/642,365	
11	NFORMATION	N DI	SCLOSURE	Filing Date	August 14, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Michael S. H. Chu	
				Art Unit	N/A .	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	Sheet 5 of 7		Attorney Docket Number	MIY-P03-024		

B3	DE 43 34 419 A1	4/13/95	Univ. Ludwigs Albert
B4	EP 0 417 189 B1	10/15/97	Boston Scientific Ireland Limited
B5	EP 0 506 920 B1	4/9/97	Salama
B6	EP 0 628 288 B1	4/5/00	Vidamed, Inc.
B7	EP 0 831 751 B1	11/6/02	Bogojavlensky et al.
B8	EP 1 159 920 A2	12/5/01	United States Surgical Corp.
B9	EP 1 321 111 A2	6/25/03	Conticare, Inc.
B10	EP 0 140 557 A3	5/8/85	Blackwood
B11	EP 0,437,063 A2	7/17/91	Vance Products
B12	EP 0,437,063 A3	7/17/91	Vance Products
B13	EP 0 599 772 A1	6/1/94	Technion Research and Development Foundation Ltd.
B14	FR 1,539,593	9/13/68	Johnson
B15	FR 2,739,016	3/28/97	Comte Georges
B16	GB 2,268,690	1/19/94	Lopez
B17	SE 503 271	3/1/96	Medscand AB
B18	SE 506 164	4/10/97	Medscand Medical AB
B19	SU 1,225,547	4/23/86	N.V. Sklifosovskii Moscow Scientific Research Institute of First Aid
B20	SU 1,443,873 A1	7/26/89	Kiev State Institute for Further Education of Physicians
B21	WO 00/74594	12/14/00	Ethicon, Inc.
B22	WO 93/10715	6/10/93	Vesitec Medical Inc.
B23	WO 93/19678	10/14/93	Vesitec Medical Inc.
B24	WO 96/01597	1/25/96	Dacomed Corporation
B25	WO 96/34587	11/7/96	Uramed Corporation
	WO 96/39227	12/12/96	Urology Inc.
B27	WO 97/13465	4/17/97	Medscand Medical
B28	WO 98/12971	4/2/98	Medworks Corporation

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	Considered	

Sut	Substitute for form 1449A/B/PTO		Complete if Known		
				Application Number	10/642,365
l IN	NFORMATION	1 DI	SCLOSURE	Filing Date	August 14, 2003
l s	STATEMENT BY APPLICANT			First Named Inventor	Michael S. H. Chu
			-	Art Unit	N/A
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	6	of	7	Attorney Docket Number	MIY-P03-024

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	Bayer et al., "A New Approach To Primary Strengthening Of Colostomy With Marlex Mesh To Prevent Paracolostomy Hernia," Surgery, Gynecology & Obstetrics, 163:579-580, (1986).	
	C2	Benderev, "A New Endoscopic Bladder Neck Suspension For The Outpatient Treatment Of Stress Urinary Incontinence," J. Urology, 149:197a (1993).	'
	C3	Benderev, "Anchor Fixation And Other Modifications Of Endoscopic Bladder Neck Suspension," Urology, 40:409-418 (1992).	
	C4	Benderev, Theodore, "A Modified Percutaneous Outpatient Bladder Neck Suspension System," J. Urology, 152:2316-2320 (1994).	
	C5	Delorme, "La Bandelette Trans-Obturatrice: Un Procede Mini-Invasif Pour Traiter l'incontinence Urinaire D'effort De La Femme," Progres En Urologie, 11:1306-1313, (2001) (English Translation Provided).	
	C6	Giesy et al., "Ureteral Instrumentation: A New System For Continued Access Via a Safety Guidewire," J. Urology, No. 4, Part 2, P.282a (1988).	
	C7	Gittes et al., "No-Incision Pubovaginal Suspension For Stress Incontinence," J. Urology, 138:3, 568-570 (1987).	
	C8	Haab et al., "Feasibility Of Outpatient Percutaneous Bladder Neck Suspension Under Local Anesthesia," Urology, 50:4, 585-897 (1997).	
	C9	Jacquetin, "Utilisation Du Tvt Dans La Chirurgie De l'incontinence Urinaire Feminine," J. Gynecol Obstet Biol Reprod., 29, 242-247 (2000).	
	C10	Kovac et al., "Public Bone Suburethral Stabilization Sling For Recurrent Urinary Incontinence," Obstetrics & Gynecology, 89:4, 624-627 (1997).	
	C11	Leach et al., "Modified Pereyra Bladder Neck Suspension After Previously Failed Anti- Incontinence Surgery: Surgical Technique And Results With Long-Term Follow-Up," Urology, 23:359-362 (1984).	
	C12	Mattox et al., "Modification Of The Miya Hook In Vaginal Colpopexy," J. Reproductive Medicine, 40:681-683 (Oct. 1995).	
	C13	Mitchell, "Hook Needle And Retractor For Posterior Urethroplasty," J. Urology, 42:599-600 (1970).	
	C14	Nativ et al., "Bladder Neck Suspension Using Bone Anchors for the Treatment of Female Stress Incontinence," Asaio Journal, 204-208 (1997).	
	C15	Norris et al., "Use Of Synthetic Material in Sling Surgery: A Minimally Invasive Approach," J. Endourology, 10:3, 227-230 (1996).	
	C16	Pereyra, "A Simplified Procedure for the Correction of Stress Incontinence in Women," West J. Surg. Obstetrics and Gynecology, 223-226 (1959).	
	C17	Petros et al., "Urethral Pressure Increase on Effort Originates From Within The Urethra, and Continence From Musculovaginal Closure," Neurology and Urodynamics, 14:4, 337-350 (1995).	
	C18	Petros, "Ambulatory Surgery For Urinary Incontinence And Vaginal Prolapse," Medical Journal Of Australia, 161:171-172 (1994).	
	C19	Petros, "Medium-Term Follow-Up Of The Intravaginal Slingplasty Operation Indicates Minimal Deterioration of Urinary Continence With Time," Aust Nz J Obstet Gynaecol., 39:3, 354-356 (1999).	
	C20	Petros, et al., "An Integral Theory and its Method For The Diagnosis and Management of Female Urinary Incontinence," Scandinavian J. Urology And Nephrology, Supplement 153, 1-93 (1993).	

Examiner	Date
Signature	Considered

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
		-		Application Number	10/642,365	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	August 14, 2003	
s	STATEMENT BY APPLICANT			First Named Inventor	Michael S. H. Chu	
_				Art Unit	N/A	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	7	of	7	Attorney Docket Number	MIY-P03-024	

C21	Petros, P., "An Integral Theory of Bladder Neck Opening, Closure and Urinary Incontinence in the Female," International Journal of Gynecology & Obstetrics, XXIII World Congress of Gynecology and Obstetrics (Figo) (1991).	
C22	Petros, P., "The Intravaginal Slingpasty Operation, A Minimally Invasive Technique for Cure of Urinary Incontinence in the Female," Aust. Nz J. Obstet Gynaecol. 36:4, 453-461 (1996).	
C23	Raz et al., "Fascial Sling to Correct Male Neurogenic Sphincter Incompetence: The Mcguire/Raz Approach," J. Urology, 139:528-531 (1988).	
C24	Raz et al., "Vaginal Wall Sling," J. Urology, 141:43-46 (1989).	
C25	Raz, "Modified Bladder Neck Suspension for Female Stress Incontinence," Urology, 17:1, 82-85 (1981).	
C26	Schaeffer et al., "Endoscopic Suspension of Vesical Neck for Urinary Incontinence," Urology 23:484-494 (1984).	
C27	Starney, T.A., "Endoscopic Suspension of the Vesical Neck for Urinary Incontinence in Females," Annals of Surgery, 192:4, 465-471 (1980).	
C28	Starney, T.A., "Endoscopic Suspension of the Vesical Neck for Urinary Incontinence," Surgery, Gynecology & Obstetrics, 136:4, 547-554 (1973).	
C29	Stamey, T.A., "Endoscopic Suspension of the Vesical Neck," Stanton, Tanagho (Eds.), Surgery of Female Incontinence, Springer-Verlag, Berlin, 115-132 (1986).	
C30	Staskin D.R., "Sling Surgery for the Treatment of Female Stress Incontinence," 5:1, 106-122, (1991).	
C31	Staskin et al., "The Gore-Tex Sling Procedure for Female Sphincteric Incontinence: Indications, Technique, and Results," World J. Urology, 15:5, 295-299, (1997).	
C32	Sussman, et al., "The Raz Bladder Neck Suspension: Five-Year Experience," J. Urology, 145, 223a, (1993).	
C33	Ulmsten et al, "Intravaginal Slingplasty (IVS): An Ambulatory Surgical Procedure for Treatment of Female Urinary Incontinence," Scand J. Urology Nephrol 29:1, 75-82 (1995).	
C34	Ulmsten et al., "A Multicenter Study of Tension-Free Vaginal Tape (TVT) for Surgical Treatment of Stress Urinary Incontinence," Int Urogynecol J., 9:4, 210-213, (1998).	
C35	Ulmsten et al., "A Three-Year Follow Up of Tension Free Vaginal Tape for Surgical Treatment of Female Stress Urinary Incontinence," British J. Of Obstetrics And Gyn., 106, 345-350, (1999).	
C36	Ulmsten et al., "An Ambulatory Surgical Procedure Under Local Anesthesia for Treatment of Female Urinary Incontinence," The International Urogynecology Journal, 7:81-86, (1996).	
C37	Ulmsten et al., "An Introduction to Tension-Free Vaginal Tape (TVT) – A New Surgical Procedure for Treatment of Female Urinary Incontinence," Int. Urogynecol J., (Suppl 2):S3-4, (2001).	
C38	Ulmsten et al., "Connective Tissue Factors in the Aeticology of Female Pelvic Disorders," Ann. Med., 22:6, 3 (1990).	
C39	Ulmsten et al., "Intravaginal Slingplasty," Zentralbl Bynakol., 116, 398-404 (1994).	
C40	Ulmsten et al., "Surgery for Female Urinary Incontinence," Current Opinion In Obstetrics & Gynecology, 4:3, 456-462, (1992).	
C41	Ulmsten, U., "The Basic Understanding and Clinical Results of Tension-Free Vaginal Tape for Stress Urinary Incontinence," Der Urologe [A] 40:269-273, (2001).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.